Kura Oncology (KURA) Competitors $10.25 +0.17 (+1.69%) Closing price 04:00 PM EasternExtended Trading$10.22 -0.03 (-0.29%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KURA vs. AMRX, CNTA, XENE, CGON, QURE, RARE, APLS, IMVT, GMTX, and OGNShould you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Amneal Pharmaceuticals (AMRX), Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Gemini Therapeutics (GMTX), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Kura Oncology vs. Its Competitors Amneal Pharmaceuticals Centessa Pharmaceuticals Xenon Pharmaceuticals CG Oncology uniQure Ultragenyx Pharmaceutical Apellis Pharmaceuticals Immunovant Gemini Therapeutics Organon & Co. Amneal Pharmaceuticals (NASDAQ:AMRX) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends. Do analysts recommend AMRX or KURA? Amneal Pharmaceuticals presently has a consensus price target of $12.00, suggesting a potential upside of 16.62%. Kura Oncology has a consensus price target of $24.10, suggesting a potential upside of 135.12%. Given Kura Oncology's higher probable upside, analysts plainly believe Kura Oncology is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Kura Oncology 2 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.59 Which has preferable earnings and valuation, AMRX or KURA? Amneal Pharmaceuticals has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.85B1.13-$116.89M$0.011,029.00Kura Oncology$53.88M16.51-$173.98M-$2.26-4.54 Is AMRX or KURA more profitable? Amneal Pharmaceuticals has a net margin of 0.12% compared to Kura Oncology's net margin of 0.00%. Kura Oncology's return on equity of -52.32% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals0.12% -189.49% 6.17% Kura Oncology N/A -52.32%-29.59% Which has more risk and volatility, AMRX or KURA? Amneal Pharmaceuticals has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Do insiders & institutionals hold more shares of AMRX or KURA? 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 26.6% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer AMRX or KURA? In the previous week, Kura Oncology had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Kura Oncology and 5 mentions for Amneal Pharmaceuticals. Kura Oncology's average media sentiment score of 0.56 beat Amneal Pharmaceuticals' score of 0.37 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAmneal Pharmaceuticals beats Kura Oncology on 10 of the 17 factors compared between the two stocks. Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KURA vs. The Competition Export to ExcelMetricKura OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$874.92M$3.37B$6.14B$10.65BDividend YieldN/A2.29%5.66%4.70%P/E Ratio-4.5421.3485.8427.65Price / Sales16.51470.58621.60138.35Price / CashN/A47.1938.3262.20Price / Book1.9310.4313.066.79Net Income-$173.98M-$52.40M$3.30B$275.88M7 Day Performance12.14%6.36%4.81%2.64%1 Month Performance27.97%16.14%9.99%9.13%1 Year Performance-44.05%33.90%85.28%35.89% Kura Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KURAKura Oncology4.1157 of 5 stars$10.25+1.7%$24.10+135.1%-44.5%$874.92M$53.88M-4.54130Analyst DowngradeAMRXAmneal Pharmaceuticals2.8651 of 5 stars$10.55+1.5%$12.00+13.7%+21.0%$3.26B$2.85B1,056.068,100Analyst ForecastCNTACentessa Pharmaceuticals3.0006 of 5 stars$23.00-1.0%$32.38+40.8%+38.7%$3.11B$6.85M-12.85200Analyst ForecastXENEXenon Pharmaceuticals2.8656 of 5 stars$39.55-0.2%$53.30+34.8%-4.3%$3.05B$7.50M-11.14210News CoverageAnalyst ForecastAnalyst RevisionCGONCG Oncology2.1965 of 5 stars$38.13-4.2%$56.55+48.3%+16.9%$3.04B$1.14M-21.5461News CoverageAnalyst ForecastQUREuniQure3.1114 of 5 stars$52.91-3.7%$71.75+35.6%+913.0%$3.01B$27.12M-13.50500Trending NewsAnalyst ForecastAnalyst RevisionRAREUltragenyx Pharmaceutical4.3816 of 5 stars$30.19-3.3%$81.50+170.0%-42.1%$3.01B$610.16M-5.461,294Analyst ForecastAPLSApellis Pharmaceuticals4.0876 of 5 stars$24.36+2.4%$33.29+36.7%-9.1%$3.01B$781.37M-13.38770Analyst ForecastIMVTImmunovant2.1088 of 5 stars$16.55-2.1%$33.20+100.6%-45.7%$2.95BN/A-5.81120GMTXGemini TherapeuticsN/A$67.78+2.9%N/A+43.4%$2.94BN/A-67.7830OGNOrganon & Co.4.7886 of 5 stars$10.84-1.5%$17.33+59.9%-43.4%$2.86B$6.40B4.034,000Analyst Forecast Related Companies and Tools Related Companies AMRX Alternatives CNTA Alternatives XENE Alternatives CGON Alternatives QURE Alternatives RARE Alternatives APLS Alternatives IMVT Alternatives GMTX Alternatives OGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KURA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
